WO2018155150A1 - Agent améliorant le taux d'acide urique dans le sang et aliment/boisson pour améliorer le taux d'acide urique dans le sang - Google Patents

Agent améliorant le taux d'acide urique dans le sang et aliment/boisson pour améliorer le taux d'acide urique dans le sang Download PDF

Info

Publication number
WO2018155150A1
WO2018155150A1 PCT/JP2018/003851 JP2018003851W WO2018155150A1 WO 2018155150 A1 WO2018155150 A1 WO 2018155150A1 JP 2018003851 W JP2018003851 W JP 2018003851W WO 2018155150 A1 WO2018155150 A1 WO 2018155150A1
Authority
WO
WIPO (PCT)
Prior art keywords
uric acid
acid level
blood uric
hesperidin
food
Prior art date
Application number
PCT/JP2018/003851
Other languages
English (en)
Japanese (ja)
Inventor
拓 平田
愛美 紺谷
Original Assignee
サッポロホールディングス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サッポロホールディングス株式会社 filed Critical サッポロホールディングス株式会社
Publication of WO2018155150A1 publication Critical patent/WO2018155150A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Definitions

  • the present invention relates to a blood uric acid level improving agent and a food and drink for improving blood uric acid level.
  • Hyperuricemia refers to a high blood uric acid level, which causes gout. Therefore, improving blood uric acid levels leads to prevention of hyperuricemia.
  • Various developments have been made so far for the purpose of preventing hyperuricemia.
  • Patent Document 1 discloses a plasma uric acid level-lowering agent containing a lemon extract obtained by extraction with a polar solvent selected from methanol, ethanol, and water as an active ingredient. .
  • An object of the present invention is to provide a novel blood uric acid level improving agent.
  • the present invention relates to a blood uric acid level improving agent comprising monoglucosyl hesperidin as an active ingredient.
  • the blood uric acid level improving agent according to the present invention contains monoglucosyl hesperidin as an active ingredient, the blood uric acid level can be improved.
  • the blood uric acid level improving agent according to the present invention is preferably an enzyme-treated hesperidin containing monoglucosyl hesperidin as an active ingredient.
  • the enzyme-treated hesperidin is preferably an enzyme-treated product of lemon extract.
  • the lemon extract is preferably a green lemon extract.
  • the blood uric acid level improving agent according to the present invention is preferably for long-term administration. Thereby, the blood uric acid level improving action is further improved.
  • the blood uric acid level improving agent according to the present invention contains monoglucosyl hesperidin as an active ingredient. Since monoglucosyl hesperidin has good water solubility, it can be dissolved or dispersed uniformly even when added to water or foods with a high water content, and therefore can be suitably used as a food or drink. Therefore, this invention relates also to the food-drinks for blood uric acid level improvement which use monoglucosyl hesperidin as an active ingredient.
  • the present invention can also be said to be a method for improving blood uric acid level, which comprises administering monoglucosyl hesperidin to a subject in need thereof.
  • the present invention can also be referred to as the use of monoglucosyl hesperidin for the production of a blood uric acid level improving agent.
  • the present invention can also be referred to as monoglucosyl hesperidin for use in improving blood uric acid levels.
  • a novel blood uric acid level improving agent can be provided.
  • Example 3 is a graph showing the results of Example 1.
  • 10 is a graph showing the results of Example 2.
  • 6 is a graph showing the results of Reference Example 1.
  • the blood uric acid level improving agent according to this embodiment contains monoglucosyl hesperidin as an active ingredient.
  • the blood uric acid level improving agent according to the present embodiment can control the blood uric acid level within a normal range or a value close to the normal range. Therefore, the blood uric acid level improving agent according to the present embodiment can also be referred to as a blood uric acid level control agent, a blood uric acid level increase inhibitor, and a blood uric acid level lowering agent.
  • the reference value of blood uric acid level is about 2.1 to 7.0 mg / dL.
  • Monoglucosyl hesperidin is a compound in which one glucose is bonded to a glucose residue in a rutinose unit of hesperidin, which is one of polyphenols contained in citrus, by an ⁇ -1,4 bond.
  • Monoglucosyl hesperidin may be a commercially available product, or may be obtained by chemical synthesis, and obtained by subjecting hesperidin to an enzyme treatment with a glycosyltransferase (eg, cyclodextrin glucosyltransferase). A thing may be used.
  • a glycosyltransferase eg, cyclodextrin glucosyltransferase
  • the blood uric acid level improving agent according to the present embodiment preferably contains enzyme-treated hesperidin containing monoglucosyl hesperidin as an active ingredient.
  • enzyme-treated hesperidin is synonymous with “enzyme-treated hesperidin” described in the list of items in the existing additive list (Japan Food Chemistry Research Foundation, revised on January 30, 2014). .
  • Enzyme-treated hesperidin is an enzyme-treated product of hesperidin and contains hesperetin glycosides such as hesperidin, ⁇ -glucosyl hesperidin, and 7-glucosyl hesperetin.
  • ⁇ -glucosyl hesperidin is a compound (glycosylated hesperidin) in which one or more glucose is bonded to a glucose residue in the rutinose unit of hesperidin by ⁇ -1,4 bond, and includes monoglucosyl hesperidin.
  • the enzyme-treated hesperidin according to this embodiment includes monoglucosyl hesperidin.
  • the content of monoglucosyl hesperidin in the enzyme-treated hesperidin may be 50 to 95 w / w%, preferably 60 to 90 w / w%, more preferably 75 to 95% based on the total amount of enzyme-treated hesperidin. It may be 85 w / w%.
  • the monoglucosyl hesperidin content in the enzyme-treated product of the lemon extract is within the above range, the blood uric acid level improving effect is further improved.
  • hesperidin When enzyme-treated hesperidin is obtained from hesperidin by enzymatic treatment, hesperidin may be one obtained by extraction from citrus fruits, one commercially available, or one obtained by chemical synthesis. Although it is good, it is preferable to use what was obtained by extraction from citrus fruits.
  • citrus fruits examples include lemon, mandarin orange and lime. These citrus fruits may be used alone or in combination of two or more.
  • the citrus fruits are preferably lemons. Thereby, since the odor derived from the extraction raw material becomes a low odor, it becomes excellent in flavor.
  • Examples of the enzyme-treated hesperidin of an extract of hesperidin derived from mandarin orange and Daidai include “ ⁇ G Hesperidin PS” and “ ⁇ G Hesperidin PA-T” manufactured by Toyo Seika Co., Ltd.
  • ⁇ G Hesperidin PS contains 85% by mass of monoglucosyl hesperidin, 1% by mass of hesperidin, and 10% by mass of 7-glucosyl hesperetin, and does not contain hesperetin.
  • “ ⁇ G Hesperidin PA-T” contains 85% by mass of monoglucosyl hesperidin and 10% by mass of hesperidin, and does not contain 7-glucosyl hesperetin and hesperetin.
  • the enzyme-treated hesperidin of the lemon-derived hesperidin extract for example, it can also be produced according to the method described in JP-A-2005-343865.
  • the lemon is preferably green lemon.
  • the green lemon means a lemon in which the peel of the lemon at the time of harvest is in a green state, so-called lemon fruit.
  • the raw material (extraction raw material) used for extraction from lemon is lemon fruit or its constituents.
  • the constituent components of fruits include fruit skin, fruit juice, scabbard, potato and seeds. From the viewpoint of easily obtaining a large amount of hesperidin among fruits or constituents thereof, it is preferable to use a peel as an extraction raw material.
  • the extraction raw material may be subjected to processing such as drying, freezing, processing, pulverization, and selection.
  • Extraction from lemon can be performed by immersing lemon in a solvent and filtering it.
  • a solvent for example, water, an alkaline aqueous solution such as an aqueous sodium hydroxide solution, an alcohol such as ethanol, or the like can be used.
  • a solvent may be used individually by 1 type, or may be used in combination of 2 or more type.
  • the lemon extract containing hesperidin can be obtained, for example, by immersing the lemon in an alkaline aqueous solution (for example, an aqueous sodium hydroxide solution), filtering it, and precipitating it under acidic conditions.
  • an alkaline aqueous solution for example, an aqueous sodium hydroxide solution
  • Enzyme-treated hesperidin is a porous synthetic adsorption resin, ion-exchange resin, after allowing hesperidin-containing material to act on a glycosyltransferase such as cyclodextrin glucanotransferase in the presence of a sugar donor such as starch, dextrin or oligosaccharide. And it can be obtained as an enzyme-treated product of hesperidin by subjecting it to a treatment such as carbon treatment.
  • the enzyme-treated product may be further treated with another enzyme (for example, a sugar hydrolase such as glucoamylase), and is purified and separated using a chromatographic separation apparatus or the like. Also good.
  • the enzyme-treated hesperidin is preferably an enzyme-treated product of a lemon extract.
  • the lemon extract is preferably a green lemon extract.
  • the analysis of monoglucosyl hesperidin and enzyme-treated hesperidin can be performed using a known method (for example, HPLC under the conditions described in the 8th edition Food Additives Official Document (Ministry of Health, Labor and Welfare).
  • the blood uric acid level improving agent contains monoglucosyl hesperidin as an active ingredient, the blood uric acid level can be improved by ingestion. Further, if a state in which the blood uric acid value concentration is high continues, it causes gout, but gout can be prevented by improving the blood uric acid value concentration. Therefore, the blood uric acid level improving agent can be used for preventing gout onset and recurrence.
  • the blood uric acid level improving agent according to the present embodiment may be in any shape such as a solid (for example, a powder), a liquid (a water-soluble or fat-soluble solution or suspension), a paste, or the like. , Tablets, capsules, solutions, suspensions, emulsions, ointments, plasters and the like. It can also take the form of a controlled release formulation.
  • the blood uric acid level improving agent according to this embodiment may be administered (ingested) to humans or administered to non-human mammals.
  • the dose (intake) of the blood uric acid level improving agent according to the present embodiment may be, for example, 10 mg to 1000 mg per day, preferably 50 mg to 800 mg, more preferably, based on monoglucosyl hesperidin. , 100 mg to 600 mg.
  • the blood uric acid level improving agent according to this embodiment may be administered orally or parenterally, but is preferably administered orally.
  • the blood uric acid level-improving agent may be administered once a day, or may be administered in a plurality of times a day as long as the dose per day is within the above range.
  • the blood uric acid level improving agent according to this embodiment can be used not only for transient blood uric acid level improvement but also for blood uric acid level improvement by long-term administration.
  • long-term administration means continuous administration (ingestion) over a period of 8 days or more.
  • the blood uric acid level improving agent according to this embodiment can be suitably used for long-term administration.
  • the blood uric acid level improving agent becomes more prominent in blood uric acid level improving effect by long-term administration.
  • the blood uric acid level improving agent according to this embodiment is preferably administered over a period of 8 days or more, more preferably administered over a period of 2 weeks or more, and administration over a period of 4 weeks or more. Is more preferable.
  • the blood uric acid level improving agent according to the present embodiment can be used as a component of products such as pharmaceuticals, quasi drugs, food and drink (beverages and foods), food and drink additives, feed and feed additives.
  • the product comprising the blood uric acid level improving agent according to the present embodiment or containing the blood uric acid level improving agent may be for blood uric acid level improvement, for blood uric acid level control, blood It may be for suppressing the increase in the middle uric acid level, for lowering the blood uric acid level, or for maintaining the blood uric acid level.
  • the above products improve blood uric acid level, control blood uric acid level, suppress blood uric acid level rise, reduce blood uric acid level, optimize blood uric acid level, For those who are concerned about the pudding of food, those who like liquor and delicious food may be displayed.
  • the food and drink for improving blood uric acid level contains monoglucosyl hesperidin as an active ingredient. Thereby, the blood uric acid level can be improved.
  • the enzyme-treated hesperidin is preferably an enzyme-treated product of lemon extract.
  • the lemon extract is preferably a green lemon extract.
  • the intake of the food for improving blood uric acid level may be, for example, 10 mg to 1000 mg per day, preferably 50 mg to 800 mg, more preferably 100 mg, based on monoglucosyl hesperidin. ⁇ 600 mg.
  • the intake of the food and beverage for improving blood uric acid level may be, for example, 13 mg to 1300 mg per day, preferably 65 mg to 1040 mg, more preferably, based on the enzyme-treated hesperidin. 130 mg to 780 mg.
  • the above-mentioned food and drink for improving blood uric acid level include beverages for improving blood uric acid level and foods for improving blood uric acid level.
  • the food / beverage product for improving blood uric acid level according to the present embodiment is not limited to transient blood uric acid level improvement, but can be used for blood uric acid level improvement by long-term administration.
  • beverage for improving blood uric acid level examples include soft drinks, fruit juice drinks, milk drinks, carbonated drinks, alcoholic drinks, non-alcoholic drinks, beer-taste drinks, sports drinks, and nutrition drinks.
  • Examples of the food for improving blood uric acid level include breads, noodles, rice, tofu, dairy products, soy sauce, miso, confectionery, and supplements. It can also be used as an ingredient involved in health foods, functional labeling foods, special-purpose foods, dietary supplements, supplements or foods for specified health use.
  • the food and drink for improving blood uric acid level may contain other components (additives) as long as the effects of the present invention are not impaired.
  • Other ingredients include, for example, sweeteners, flavorings, acidulants, colorants, antioxidants, seasonings, vitamins, minerals, pH adjusters, stabilizers, gelling agents, dietary fiber, and indigestible Dextrin and the like can be used. These components can be used individually by 1 type or in combination of 2 or more types.
  • Sweeteners include sugar, tri-sugar, brown sugar, honey, reduced starch saccharified, oligosaccharides, sugar alcohols, sugars such as rare sugars, sucralose, aspartame, acesulfame potassium, saccharin, alitame, neotame, etc. Sweeteners and the like can be used. These sweeteners can be used alone or in combination of two or more.
  • any natural or synthetic fragrance can be used. Although it does not specifically limit as a fragrance
  • flavors can be used individually by 1 type or in combination of 2 or more types.
  • the sour agent can be used without particular limitation as long as it is used for food and drink.
  • the acidulant for example, citric acid, lactic acid, malic acid, phosphoric acid, succinic acid, tartaric acid, acetic acid and the like can be used. These acidulants can be used alone or in combination of two or more.
  • coloring agent any natural coloring agent or synthetic coloring agent can be used as long as it is used for coloring food and drink.
  • colorant for example, caramel color, gardenia color, marigold color, carotene color, anthocyanin color, fruit juice color, vegetable color, synthetic color and the like can be used.
  • dyes can be used individually by 1 type or in combination of 2 or more types.
  • the food and drink for improving blood uric acid level may be a container-packed food and drink.
  • a container in the case of a container-packed food or drink for example, a glass bottle, a resin molded container, a metal can, a metal foil, a paper container combined with a plastic film, or the like can be used, as in a general food or drink.
  • the type, shape and color of the container are not particularly limited.
  • Examples of the resin constituting the resin-molded container include polyester resins such as polyethylene terephthalate and polybutylene terephthalate, and polyolefins such as polyethylene, polypropylene, and polybutylene.
  • the weight average molecular weight, crystallinity, and the like of these resins are not particularly limited, and can be appropriately selected according to the distribution conditions, storage conditions, and the like of the food and drink.
  • a resin-made container using polyethylene terephthalate is generally called a PET bottle. PET bottles are classified into aseptic PET bottles assuming normal temperature filling (aseptic filling) of foods and drinks, filling foods and drinks while performing heat sterilization, or heat-resistant PET bottles assuming hot sales. However, any of them can be used in the present embodiment.
  • metal cans examples include steel cans, aluminum cans and tin cans.
  • ⁇ / RTI> When the food / beverage for improving blood uric acid level according to the present embodiment is used as a container-packed food / beverage, sterilization may be performed as necessary.
  • Examples of the sterilization and container filling in the case of a container-packed food / beverage product include heat sterilization under conditions defined in the Food Sanitation Law after filling a metal can.
  • a method for improving blood uric acid level comprising administering monoglucosyl hesperidin to a subject in need thereof.
  • use of monoglucosyl hesperidin for manufacture of a blood uric acid level improving agent is provided as one Embodiment of this invention.
  • monoglucosyl hesperidin for use in improving blood uric acid levels is provided.
  • the administration method, administration subject, dosage and the like may be the same as those in the blood uric acid level improving agent.
  • the reaction solution was passed through a column packed with a porous synthetic resin adsorbent (trade name “HP-10”, manufactured by Mitsubishi Kasei Co., Ltd.) at SV 2.0 to adsorb enzyme-treated hesperidin.
  • a porous synthetic resin adsorbent trade name “HP-10”, manufactured by Mitsubishi Kasei Co., Ltd.
  • this column was washed with water to wash and remove dextrin decomposition products and odorous substances, and then passed through a 50 v / v% aqueous ethanol solution to desorb enzyme-treated hesperidin and the like.
  • the obtained desorption solution was concentrated to remove ethanol in the eluate to obtain a dry powder.
  • powdered activated carbon (trade name “Purified Shirakaba”, manufactured by Takeda Food Industry Co., Ltd.) was added to the obtained effluent and stirred at 60 ° C. for 1 hour. Next, the powdered activated carbon was removed by filtration, followed by concentration and drying to obtain a powdered green lemon extract enzyme-treated product (hereinafter also referred to as “GLPP”) as enzyme-treated hesperidin.
  • GLPP powdered green lemon extract enzyme-treated product
  • GLPP contains a high content of monoglucosyl hesperidin.
  • Example 1 Acute test
  • SD rats male, 5 weeks old were bred for 1 week under free feeding conditions of CRF-1 feed (Oriental Yeast Co., Ltd.) and tap water under the breeding conditions of a temperature of 23 ⁇ 1 ° C. and a humidity of 55%.
  • Five animals (GLPP group) were orally administered GLPP at 500 mg / kg, and oxonic acid was administered intraperitoneally at 250 mg / kg 2 hours after GLPP administration, and changes in blood uric acid levels over time were examined. Further, in the same manner as described above except that GLPP was not administered, the same amount of sterile physiological saline was orally administered to the control group, and the change in blood uric acid level over time was examined.
  • the blood uric acid level was measured at 0, 1, 2, and 4 hours with reference to the time point of administration of oxonic acid (0 hour), and the measurement sample was obtained by collecting blood from the rat tail vein. Moreover, the change rate of the blood uric acid level was calculated based on the blood uric acid level (1.0) of each individual 2 hours before the oxonic acid administration (in the GLPP group, at the time of GLPP administration).
  • uric acid synthesized in the purine metabolism pathway is rapidly metabolized to allantoin by an enzyme called uricase, and thus the serum uric acid level is usually kept low. Therefore, a rat in which uric acid metabolism was suppressed by oxonic acid, a uricase inhibitor, was used as a hyperuricemia model rat.
  • the blood uric acid level was measured by the following method. Specifically, 90 ⁇ L of distilled water was added to 10 ⁇ L of the serum to be measured, diluted, and further 20 ⁇ L of 10% trichloroacetic acid / water was added to remove protein. After mixing, the vortexed sample was allowed to stand on ice for 30 minutes and centrifuged. (15,000 rpm, 10 min, 4 ° C.). The obtained supernatant was filtered through a 0.45 ⁇ m filter and subjected to LC-MS / MS analysis under the following conditions. As a sample, uric acid (manufactured by Wako Pure Chemical Industries, Ltd.) was used.
  • Fig. 1 shows the rate of change of uric acid value measurement results.
  • the value of the graph represents the average value of the uric acid value change rate in each group, and the error bar represents its standard error.
  • FIG. 1 it was shown that the increase in blood uric acid level was suppressed by ingesting GLPP containing monoglucosyl hesperidin before the treatment for increasing the uric acid level in rats.
  • mice 7-week-old, C57BL / 6J mice, Charles River
  • mice were subjected to testing at the age of 8 weeks after one week of acclimatization.
  • the mice were housed in an environment with a temperature of 23 ⁇ 1 ° C., a humidity of 55%, and a 12-hour light-dark cycle.
  • the feed during the acclimatization period was MF feed (Oriental Yeast Co., Ltd.), and feed and tap water were freely consumed.
  • the GLPP group fed with a diet mixed with 0.5% and 1.0% GLPP is hereinafter also referred to as “0.5% GLPP group” and “1.0% GLPP group”, respectively.
  • the 60% fructose diet contained in the test diet is a diet that increases the uptake of glucose without insulin through the liver and promotes the synthesis of purine, a substrate for uric acid, and has been reported to increase serum uric acid levels in mice Has been. Further, as in Example 1, hyperuricemia model mice were prepared by feeding with potassium oxonate, which is a uricase inhibitor. Furthermore, 3% uric acid was mixed.
  • Fig. 2 shows the measurement results of blood uric acid levels.
  • the results of measurement of blood uric acid levels in mice of each group at 0 weeks, 2 weeks and 4 weeks after the start of the test are shown in FIGS. 2 (a), 2 (b) and 2 (c), respectively.
  • the value in the graph represents the average value of blood uric acid in each group, and the error bar represents the standard error. 0.5% and 1% in the table indicate “0.5% GLPP group” and “1.0% GLPP group”, respectively.
  • FIG. 2 it was shown that an increase in blood uric acid level was suppressed by ingesting GLPP containing monoglucosyl hesperidin. That is, a significant difference can be confirmed by t-test in the 0.5% and 1.0% GLPP groups at both 2 weeks and 4 weeks, and a significant long-term increase in blood uric acid level is suppressed. I was able to confirm that.
  • the rate of decrease in blood uric acid level after 2 weeks was 27% and 31%, respectively, and the rate of decrease in blood uric acid level after 4 weeks was 35 respectively. % And 38%.
  • the rate of decrease in blood uric acid level (%) is the difference between the blood uric acid level (average value) of the control group mice and the blood uric acid level (average value) of the GLPP group mice. It is the ratio to the blood uric acid level (average value) of the group mice.
  • mice (7-week-old, C57BL / 6J mice, Charles River) were subjected to testing at the age of 8 weeks after one week of acclimatization. Throughout the acclimatization period and subsequent test periods, the mice were housed in an environment with a temperature of 23 ⁇ 1 ° C., a humidity of 55%, and a 12-hour light-dark cycle. The feed during the acclimatization period was MF feed (Oriental Yeast Co., Ltd.), and feed and tap water were freely consumed.
  • MF feed Oriental Yeast Co., Ltd.
  • hesperidin administration test 2-3 animals / cage were housed in a plastic ino cage for 2 weeks.
  • 0.39% hesperidin corresponds to 0.50% GLPP.
  • FIG. 3 shows the measurement results of blood uric acid levels in the hesperidin group and the control group.
  • the blood uric acid level measurement results of the mice in each group at 0 and 2 weeks after the start of the test are shown in FIGS. 3 (a) and 3 (b).
  • the value in the graph represents the average value of blood uric acid in each group, and the error bar represents the standard error.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne un agent améliorant le taux d'acide urique dans le sang comprenant de la monoglucosyle hespéridine en tant que principe actif.
PCT/JP2018/003851 2017-02-21 2018-02-05 Agent améliorant le taux d'acide urique dans le sang et aliment/boisson pour améliorer le taux d'acide urique dans le sang WO2018155150A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017030408A JP6942483B2 (ja) 2017-02-21 2017-02-21 血中尿酸値改善剤及び血中尿酸値改善用飲食品
JP2017-030408 2017-02-21

Publications (1)

Publication Number Publication Date
WO2018155150A1 true WO2018155150A1 (fr) 2018-08-30

Family

ID=63253228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/003851 WO2018155150A1 (fr) 2017-02-21 2018-02-05 Agent améliorant le taux d'acide urique dans le sang et aliment/boisson pour améliorer le taux d'acide urique dans le sang

Country Status (2)

Country Link
JP (1) JP6942483B2 (fr)
WO (1) WO2018155150A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020226165A1 (fr) * 2019-05-08 2020-11-12 国立大学法人大阪大学 COMPOSITION DESTINÉE À INHIBER L'ACCUMULATION D'α-SYNUCLÉINE ET COMPOSITION DESTINÉE À INHIBER LA PROPAGATION D'AGRÉGATS D'α-SYNUCLÉINE

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7041016B2 (ja) 2018-07-18 2022-03-23 株式会社シマノ 人力駆動車用装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010059104A (ja) * 2008-09-04 2010-03-18 Pokka Corp キサンチンオキシダーゼ阻害剤
CN104224863A (zh) * 2014-06-25 2014-12-24 苏州凯祥生物科技有限公司 金钱草总黄酮在制备降低高尿酸血症药物中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010059104A (ja) * 2008-09-04 2010-03-18 Pokka Corp キサンチンオキシダーゼ阻害剤
CN104224863A (zh) * 2014-06-25 2014-12-24 苏州凯祥生物科技有限公司 金钱草总黄酮在制备降低高尿酸血症药物中的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANANDAN, RAMASWAMY ET AL.: "Renal protective effect of hesperidin on gentamicin-induced acute nephrotoxicity in male Wistar albino rats", REDOX REPORT, vol. 17, no. 5, 2012, pages 219 - 226, XP055538813 *
MITSUZUMI, HITOSHI: "Possibilities of glucosyl hesperidin, a citrus polyphenol, in the field of functional foods", JOURNAL FOR THE INTEGRATED STUDY OF DIETARY HABITS, vol. 21, no. 4, 2011, pages 263 - 267, XP055538809 *
NAKAO, KIKUYO ET AL.: "Anti-hyperuricemia effects of extracts of immature Citrus unshiu fruit", JOURNAL OF TRADITIONAL MEDICINES, vol. 28, no. 1, 2011, pages 10 - 15, XP055538812 *
YAMADA, MIKA ET AL.: "Bioavailability of Glucosyl Hesperidin in Rats", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, vol. 70, no. 6, 23 June 2006 (2006-06-23), pages 1386 - 1394, XP009136975 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020226165A1 (fr) * 2019-05-08 2020-11-12 国立大学法人大阪大学 COMPOSITION DESTINÉE À INHIBER L'ACCUMULATION D'α-SYNUCLÉINE ET COMPOSITION DESTINÉE À INHIBER LA PROPAGATION D'AGRÉGATS D'α-SYNUCLÉINE

Also Published As

Publication number Publication date
JP6942483B2 (ja) 2021-09-29
JP2018135295A (ja) 2018-08-30

Similar Documents

Publication Publication Date Title
JP3896577B2 (ja) クエルセチン配糖体組成物およびその調製方法
JP6222626B2 (ja) フルクトース吸収阻害剤
KR0165956B1 (ko) 알파-글리코실 루틴을 함유시킨 음식물의 제조방법
KR101880768B1 (ko) 콜라겐 펩티드 함유 조성물의 제조 방법
EP2754444B1 (fr) Composition pour améliorer un paramètre du métabolisme in vivo
JP5000373B2 (ja) 水溶性フラボノイド組成物およびその製造方法、ならびに水溶性フラボノイド組成物を含む食品等
JP2013507914A (ja) 高純度のレバウジオシドｄとその適用
TW200738176A (en) High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith
KR0156539B1 (ko) 4지-o-알파-디이-글루코피라노실 루틴 및 그 제조 방법
JP6251760B2 (ja) 容器詰発泡飲料
JPH0327293A (ja) α―グリコシル　ルチンの製造方法とその用途
WO2018155150A1 (fr) Agent améliorant le taux d'acide urique dans le sang et aliment/boisson pour améliorer le taux d'acide urique dans le sang
JP5042519B2 (ja) ナリンジン組成物、その製造方法及び用途
JP4846141B2 (ja) 即効性および持続性を有するフラボノイド配糖体を含有する経口栄養補給剤
EP1837026A1 (fr) Agent therapeutique pour la fonction hepatique
JP4982656B2 (ja) 水可溶性イソフラボン組成物およびその製造方法並びにその用途
JP2009062301A (ja) ヤエヤマアオキエキスおよびその利用
TW201927162A (zh) 含有吡咯并喹啉醌的酸性飲料及吡咯并喹啉醌的析出抑制方法
JP2009209066A (ja) 生体吸収性に優れたヘスペレチン組成物
JP4051482B2 (ja) α−グリコシルヘスペリジンを含んでなる医薬組成物
Borrego et al. Neohesperidin dihydrochalcone
JP7160567B2 (ja) 食品および酸味改善剤
EP4309515A1 (fr) Composition favorisant la sécrétion de glp-1
KR100227598B1 (ko) 신규의α-글리코실나린진을함유시킨화장품
JP2023103165A (ja) Ａｔｐ産生促進剤、抗炎症剤及び飲食品

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18756719

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18756719

Country of ref document: EP

Kind code of ref document: A1